Tilavonemab (ABBV-8E12), a humanized anti-tau antibody, targets amino acids 25-30 near the tau protein's N-terminal end. It inhibits the uptake of tau aggregates by human and mouse neurons and diminishes brain atrophy, making it a potential tool in Alzheimer's disease research .

AMPA is the definitive agonist of the AMPA glutamatergic ionotropic receptor

Schisantherin A, B, C, and D show good effect in lowering the serum glutamic-pyruvic transaminase level of the patients suffering from chronic virus hepatitis.